Feasibility Study of Developing a Saline-Based Antiviral Nanoformulation Containing Lipid-Soluble EGCG: A Potential Nasal Drug to Treat Long COVID.

Nicolette FrankDouglas DickinsonWilliam GarciaYutao LiuHongfang YuJingwen CaiSahaj PatelBo YaoXiaocui JiangStephen Hsu

Published in: Viruses (2024)

Nanoformulations containing EC16 showed properties compatible with nasal application to rapidly inactivate SARS-CoV-2 residing in the olfactory mucosa and to reduce inflammation in the CNS, pending additional formulation and safety studies.

Keyphrases

sars cov
chronic rhinosinusitis
respiratory syndrome coronavirus
oxidative stress
coronavirus disease
drug delivery
blood brain barrier
case control
emergency department
adverse drug